Novo Holdings announces 2025 Annual Results Novo Holdings announced its financial results for 2025. Despite a challenging global environment, Novo Holdings has made significant progress on its Strategy 2030 during 2025 and delivered on its priorities. The Novo Holdings Investment Portfolio continued to perform well on both an absolute and relative basis, with a return […]
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
